The evidence position
FDA: “the effects of epitalon on sleep behavior are unknown” (slide 18), and the relationship between epitalon-induced upregulation of telomerase and sleep “is currently unknown.” (slide 19)
FDA: “There are no publications that discussed efficacy of epitalon administered in patients with insomnia.” (slide 21) The one human study FDA identified has “small sample size, short duration, and unclear whether blinded for bias control”, and “did not evaluate sleep outcomes.” (slide 22)
FDA “did not identify, additional nonclinical pharmacokinetic, toxicokinetic, or general toxicity studies” (slide 24), and states “nonclinical studies available at the time of this evaluation were too limited to inform safety considerations.” (slide 26) FDA also states “there is no clinical data to support the safety of epitalon.” (slide 30)
Not named on the WADA Prohibited List. Note that class S0 covers substances with no current approval for human therapeutic use, so absence from the list is not a clearance.
In July 2026 the US Food and Drug Administration reviewed Epitalon for the 503A Bulk Drug Substances list and proposed that it not be included. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026.
The pathways it is reached for
Telomerase — the enzyme that maintains the protective caps on chromosomes, offsetting the shortening that limits cellular lifespan.
Melatonin — the hormone of biological night that entrains the body clock and opens the gate to sleep.
Melatonergic circadian entrainment — the alignment of the internal clock with the day–night cycle.
Senescence and its inflammatory sasp — cells that stop dividing yet linger, spilling signals that age the surrounding tissue.
The senescence-associated secretory phenotype â what a senescent cell says to its neighbors. Self-reinforcing: sasp drives inflammaging, and inflammaging drives more sasp. An arrow encodes one pass of a loop.
What we carry on those pathways
Shares 2 of these pathways: Senescence / SASP, SASP (Senescent Secretome).
Shares 2 of these pathways: Melatonin, Circadian Rhythm.
Circadian Rhythm → ADHD. “Cry1Δ11 (c. 1717 + 3A > C) mice showed ADHD-like symptoms, including hyperactivity, impulsivity, and deficits in learning and memory.” — Cry1Δ11 mutation induces ADHD-like symptoms through hyperactive dopamine D1 receptor signaling. JCI Insight 2023;8(16):e170434; eISSN 2379-3708; publisher American Society for Clinical Investigation. doi:10.1172/jci.insight.170434
Circadian Rhythm → Cognition. “Circadian disruption resulted in pronounced deficits in learning and memory paralleled by marked reductions in hippocampal cell proliferation and neurogenesis.” — Experimental 'Jet Lag' Inhibits Adult Neurogenesis and Produces Long-Term Cognitive Deficits in Female Hamsters. PLoS ONE, 2010, vol 5, e15267. doi:10.1371/journal.pone.0015267
Melatonin → Sleep. “Melatonin decreases sleep onset latency, increases total sleep time and improves overall sleep quality.” — Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLoS ONE, 2013, volume 8, issue 5, e63773. doi:10.1371/journal.pone.0063773
Senescence / SASP → CD38 NADase. “We also find that senescent cells progressively accumulate in visceral white adipose tissue and liver during ageing and that inflammatory cytokines secreted by senescent cells (the senescence-associated secretory phenotype, SASP) induce macrophages to proliferate and express CD38.” — Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism, 2020, vol 2, 1265-1283. doi:10.1038/s42255-020-00305-3
Senescence / SASP → Muscle Recovery. “Reducing the burden of senescent cells, or reducing their inflammatory secretome through CD36 neutralization, accelerates regeneration in young and old mice.” — Senescence atlas reveals an aged-like inflamed niche that blunts muscle regeneration. Nature, 2023, volume 613, issue 7942, pages 169-178. doi:10.1038/s41586-022-05535-x
Senescence / SASP → Type 2 Diabetes. “Emerging evidence from animal and clinical studies suggests that the usage of senolytic drugs, which selectively deplete senescent cells, can improve blood glucose regulation and mitigate diabetic complications.” — Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions. Diabetology, 2025, volume 6, issue 6, article 48. doi:10.3390/diabetology6060048
What a grade means here
Every ingredient row on our formula pages carries one of these grades, fixed by a standard set before the evidence was gathered. The grades below are reproduced from those pages.
Randomized human trials, or a meta-analysis of them, measuring this pathway's own endpoint — either a clinical outcome or a validated biomarker.
Human data, or animal evidence replicated by an independent laboratory. It opens a pathway only alongside an independent corroborating driver.
Mechanistic, cell or animal evidence. No single preclinical driver opens a pathway on its own.
What this page does not claim
Sharing a pathway is not the same as sharing an effect. Nothing here says a botanical formula does what Epitalon does, and nothing here recommends Epitalon. The pathways above are named because that is what the published work on Epitalon points at; the formulas below are listed because our own map records graded, published evidence on those same pathways. Read both columns and judge them yourself — every figure on our side carries its grade and its source.